Your session is about to expire
← Back to Search
MRX-2843 + Osimertinib for Lung Cancer
Study Summary
This trial is testing a combination of drugs to see if they are effective in treating patients with lung cancer that has spread to other parts of the body. The drugs may work by blocking enzymes needed for cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have enough platelets in your blood.I agree to use birth control during and up to 4 months after the study.I agree to use two forms of birth control during and for 90 days after the study if I can have children and am sexually active with a man.I can safely take pills by mouth.You have enough white blood cells called neutrophils in your body.My lung cancer has a specific EGFR mutation.I have not taken osimertinib or any EGFR TKI for my condition, or if I have, it was over a year ago without recurrence.My bilirubin levels are within the normal range, even with liver issues or Gilbert's disease.I am a man who can father children and will use birth control during and for 3 months after the study.I can take care of myself and am up and about more than half of the day.My kidney function, measured by creatinine levels or clearance, is within the required range.I am not taking any drugs that affect liver enzymes.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I do not have symptoms from untreated brain metastases.My hemoglobin level is at least 8.5 g/dL and I haven't had a blood transfusion in the last 2 weeks.My cancer progressed after treatment with specific EGFR inhibitors and I am not positive for EGFR-T790M mutation.I am eligible for the backfill cohort because I don't fit into other groups but meet the general requirements.I am not pregnant or breastfeeding.My liver enzymes are within the required limits.I have a tumor that can be measured and is big enough according to specific guidelines.My heart's electrical activity (QTc interval) is normal and I have no family history of long QT syndrome.I have been diagnosed with interstitial lung disease or pneumonitis.I have a heart condition with reduced heart pump function.I have or might have retinitis pigmentosa, or it runs in my family.I have had keratitis or symptoms like eye pain, redness, or blurred vision.I am allergic to medications similar to MRX-2843 or osimertinib.I am not pregnant and have negative pregnancy tests before treatment.You are currently taking any experimental drugs.I do not have HIV or I am not on HIV medication.I have NSCLC with worsening condition, previously treated or not with EGFR-TKI.I have type 1 diabetes or am at high risk due to family history and my A1C is over 6.5%.I haven't had chemotherapy or radiotherapy in the last 4 to 6 weeks.I have no lasting side effects from previous cancer treatments above mild.
- Group 1: Treatment (osimertinib, MRX-2843)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still vacancies for patients to join this experiment?
"As indicated on the clinicaltrials.gov database, this trial is actively enrolling participants and was first introduced to the public on February 24th 2021 with its most recent update occuring on March 8th 2022."
What evidence is there to support the efficacy of Flt3/MerTK Inhibitor MRX-2843?
"Currently, 101 investigations into Flt3/MerTK Inhibitor MRX-2843 are taking place with 17 trials in the final stage. Out of Uniondale, New york several studies on this subject matter have been initiated and a grand total of 4702 locations are running clinical trials for Flt3/MerTK Inhibitor MRX-2843."
Is this a pioneering research project?
"Since 2013, research into Flt3/MerTK Inhibitor MRX-2843 has been ongoing. It was initially sponsored by AstraZeneca in a study involving 603 patients. Following the first trial, it received its Phase 1 & 2 drug approval and is now currently being studied across 1059 cities within 51 nations with 101 active trials."
How many volunteers have participated in this experiment?
"Affirmative. The clinical trial is currently recruiting, as evidenced by the data hosted on clinicaltrials.gov from its inception date of February 24th 2021 and latest update on March 8th 2022. 69 volunteers are being sought across a single site for recruitment."
Could you please expound on the risks of Flt3/MerTK Inhibitor MRX-2843?
"Assessing the safety of Flt3/MerTK Inhibitor MRX-2843 on a scale from 1 to 3, our team at Power have assigned it a score of 1 as this is still in its early Phase 1 trial and there is limited evidence regarding efficacy and safety."
Share this study with friends
Copy Link
Messenger